Big Pharma R&D needs help. Really!?

It was proved that Big Pharma is not interested in development of innovative products no matter what it says. Instead of doing real development it usually simulates it. The simulation “convinces” public that Big Pharma invests a lot but in reality the resources are just burned. The next simulation initiative is astonishing (see also here):

Ten big drug companies shared today that they have created a non-profit organization to help speed up the R&D of new drugs. These companies are Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Johnson & Johnson, Pfizer, Roche, and Sanofi. Together, they are unveiling TransCelerate BioPharma Inc. This is the largest initiative of its kind, and it is designed to identify and resolve common issues that can delay R&D. Read the release here.

By participating in TransCelerate, each of these companies will combine financial and other resources, such as personnel, to work out industry wide challenges in a team work atmosphere.

Back in June, Ernst & Young released its “Beyond Borders: Global Biotechnology Report 2012,” which addressed some of the problems in R&D and suggested that companies, academia, and nonprofit groups should strive to share noncompetitive data in networks called HOLnets to improve drug development.

I like this simulation initiative! Big Pharma which invests billions and billions every year needs more resources (!), needs more collaboration (!) to develop something worthwhile! This is completely sick!